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Summary Platelet sensitivity to prostacyclin (PG12) was determined in normal male and female subjects, and
in patients with benign and malignant tumours of the breast.
The IC50 overall mean values for PG12 on ADP-induced platelet aggregation were similar for normal men
and women, being 0.97+0.05 ngml- and 0.83 +0.07 ngml- respectively. However, there were significant
differences in the IC50 values for women in the 1st (0.81 +0.06 ngml-1) vs. 2nd (1.37+0.13 ngml-1) phase of
the menstrual cycle; post-menopausal women gave similar values to normal males and to pre-menopausal
women in the 1st phase of the cycle.
No significant differences were found between normal subjects and patients with benign or malignant
tumours of the breast when account was taken of the status of the patient in relation to the phase of the
menstrual cycle and the menopause.
The importance of the hormonal status in evaluating changes in platelet sensitivity in patients with breast
cancer is strongly emphasised.
Prostacyclin (PGl2) may play an important role in
the control of vascular and platelet homeostasis
(Bunting et al., 1983). Based upon the assumption
that platelet-tumour cell and/or platelet-tumour
cell-vessel wall interactions can influence the
metastasis of tumour cells, Honn and coworkers
(Honn, 1982; Honn et al., 1983) suggested that the
presence of malignant tumours could disrupt the
intravascular balance between PG12 and
thromboxane A2 (TXA2), the main endogenous
antagonist of PG12 (Bunting et al., 1983), in favour
of platelet aggregation, thus favouring the
likelihood of metastasis.
Another factor that may contribute to changes in
platelet aggregation in patients with tumours is the
sensitivity of the platelets to PGl2. This aspect may
be investigated in vitro using synthetic PGI2, and
probably is an essential part of the biological
activity of PG12 through its binding to platelet
membranes, and in the regulation of haemostatic
balance (Schillinger & Prior, 1980).
Since studies on humans have demonstrated that
patients with colonic cancer have a decreased
platelet sensitivity to PG12 (Gisinger et al., 1982)
and malignant tumours of the breast produce sub-
stantial amounts of PG12 (Bennett et al., 1983) we
decided to investigate the platelet sensitivity to PG12
in patients with benign and malignant tumours of
the breast.
Subjects and methods
Subjects
Four groups of subjects have been studied:
1) 26 healthy normal female subjects;
2) 14 patients with benign tumours of the breast;
3) 30 patients with malignant tumours of the
breast;
4) 16 men as healthy controls.
The range and mean values +s.d. of ages of all
subjects and the number of women in pre- and
post-menopause are given in Table I. None of the
subjects was on oral contraceptives and 7 healthy
women in pre-menopause were studied both in the
first and second phase of the same cycle. In 4
normal subjects the estimations were repeated
during different menstrual cycles. Eight men, 1
woman with a malignant tumour and I with a
benign tumour of the breast smoked more than 10
cigarettes a day; none of the subjects had taken
drugs known to affect prostaglandin metabolism in
the two weeks before the blood sampling, or had
diabetes mellitus or coronary heart diseases. In the
group with malignant tumours 3 patients had
hypertension, 3 were obese.
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Table I Clinical data on the subjects studied. For details see the text; mean values are given+s.d.
Pre-menopause
Age (years) Ist phase of 2ndphase of
Groups of the cycle the cycle Post-menopause
subjects Pre-menopause Post-menopause Total (n) (n) (n)
1. Healthy women 28+4 54+4 41+14 12 8 13
(n =26) (24-37) (48-61) (24-61)
2. Women with 39+6 39+6 6 8
benign breast (31-49) (31-49)
tumours
(n= 14)
3. Women with 45+7 61+10 53+12 6 8 16
malignant breast (33-35) (45-77) (33-77)
tumours
(n=30)
4. Healthy men 31 +8
(n= 16) (25-54)
Histopathological data on benign and malignant
tumours
The benign tumours of the breast were all fibro-
adenomas. The malignant tumours included: 20
infiltrating duct carcinomas, 4 infiltrating lobular
carcinomas, 1 colloid papillary infiltrating
carcinoma, 1 colloid infiltrating carcinoma, 2 in situ
duct carcinomas and 2 in situ lobular carcinomas.
Eleven tumours had a maximum diameter greater
than 2cm and lymph node metastases were present
in 16 patients.
Blood sampling
Blood samples were always taken between 8 and
9a.m.; the subjects had fasted overnight prior to
the sampling.
The blood was drawn from the antecubital vein
with a polypropylene syringe via a Butterfly needle
No. 21 (Abbott Ireland Ltd., Sligo, Rep. of
Ireland), placed in a plastic tube containing one
tenth of its volume of 3.3% (w/v) trisodium citrate
and quickly mixed.
Preparation ofplatelet-rich andplatelet-poor plasma
Platelet-rich plasma (PRP) was obtained by
centrifuging blood at 150g for 12min. Platelet-poor
plasma (PPP) was prepared by centrifugation of the
remaining blood at 2000g for 15min. The platelet
count of PRP was adjusted to 250 x 103cellsyl
- I by
dilution with homologous PPP. The PRP and PPP
were kept at room temperature (- 22°C).
Platelet sensitivity to PG12
The platelet sensitivity to PG12 in the plasma was
determined using a modification of the method of
Sinzinger et al. (1981).
Platelet aggregation was studied using 250 p1 of
PRP in a double-channel Elvi aggregometer at 37°C
with constant stirring. Following a preincubation
period of 15 sec, 20,u1 of different concentrations of
standard PG12 in Tris buffer (50pM, pH9.5) were
added to the PRP min before the addition of
ADP (final concentration 1 pM).
The platelet sensitivity to prostacyclin was
expressed as the dose of the synthetic PG12 (in
ngml-1 PRP) necessary to suppress by half the
aggregation induced by ADP (IC50).
Chemicals
ADP was obtained from Semmelweis s.r.l.-Mascia
Brunelli (Milano, Italy). PG12 standards were kindly
provided by Dr J. Pike (Upjohn Company,
Kalamazoo, Michigan, U.S.A.) and by Dr B.J.R.
Whittle (Wellcome Foundation, Beckenham, Kent,
U.K.).
Statistics
Statistical evaluations were made by Student's t-
test. Differences and correlations were considered
significant when P<0.05.
Results
The mean values +s.e. of the IC50 for prostacyclin
on the ADP-induced platelet aggregation assay are
shown in Table II for the 4 groups of subjects
studied: where appropriate, the groups are sub-
divided so as to separate values found during thePLATELET SENSITIVITY TO PROSTACYCLIN IN BREAST CANCER 51
Table II Mean values+s.e. for the IC50 in ngml-I that corresponds to the inhibitory effect of PGl2 on
ADP-induced platelet aggregation. Group 1: normal female control subjects; Group 2: patients with benign
breast tumours; Group 3: patients with malignant breast tumours; Group 4: normal male subjects. Where
appropriate, the values have been sub-divided to indicate where samples were obtained during the 1st or 2nd
phases of the menstrual cycle, and after the menopause. For further details see the text.
PGl2 IC50ngml-l
1st phase of 2ndphase of Ist & 2ndphases
Groups of All values cycle cycle ofcycle Post-menopause
subjects (a) (b) (c) (d) (e)
1. Healthy women 0.97+0.05 0.81 +0.06 1.37+0.13 1.02+0.08 0.86+0.04
(n=39) (n= 16) (n= 10) (n=26) (n= 13)
2. Women with 1.06+0.08 0.86+0.10 1.21+0.10 1.06+0.08
benign breast (n= 14) (n=6) (n=8) (n= 14)
tumours
3. Women with 0.99+0.06 0.83+0.13 1.18+0.20 1.03+0.12 0.96+0.06
malignant breast (n=30) (n=6) (n=8) (n=14) (n = 16)
tumours
4. Healthy men 0.83+0.07
(n =16)
Statistical significance: l(b) vs. l(c), P<0.001; l(c) vs. 1(e), P<0.001; 2(b) vs. 2(c), P<0.05.
first or second phases of the menstrual cycle, and
after the menopause.
It can be seen by inspection of column "a" of
Table II that there is no significant difference
between the mean values for all subjects studied in
Group 1 (normal females) and Group 4 (normal
males). Moreover, there is no significant difference
in the overall mean values for patients with
tumours of the breast (Table II, column "a";
Groups 2 and 3) and normal female subjects
(Group 1).
In contrast to the lack of significant differences
between the overall mean values just mentioned,
when the female Groups 1-3 are separated into first
or second phases of the menstrual cycle and post-
menopausal sub-groups (Table II, columns "b",
"c", "e") then significant differences become
evident. There is a considerable increase in the IC50
values for healthy women in the second phase of
the cycle compared to the first phase; the post-
menopausal sub-group (column "e") for normal
women gives a mean value that is very similar to
that obtained in the first phase of the cycle in pre-
menopausal subjects. The stage of the cycle in the
subjects studied was calculated on the basis of the
time from the onset of menstruation, and, in some
normal subjects, was checked by measurements of
body temperature and progesterone levels in the
plasma. Where the progesterone concentration
indicated a failure of ovulation the value for the
second phase of the cycle was deleted (3 subjects).
In fact where progesterone had not increased in the
presumed second phase of the cycle, the IC50 value
was in the range typical of first phase samples. The
latter result suggests that the change in IC50 that is
observed between the first and second phases of the
cycle is probably a more or less direct consequence
of hormonal influences.
The mean value for normal males (Group 4,
column "a") corresponds to that found for normal
pre-menopausal women in the first phase of the
cycle, and for post-menopausal women.
Although the overall difference between the mean
values obtained for first and second phases of the
menstrual cycle is not so large in patients with
tumours of the breast (Groups 2 and 3) as in
normal subjects (Group 1), the same phenomenon
is observed: a higher value for IC50 in the second
phase compared to the first phase of the cycle. This
difference is statistically significant for the benign
tumour group, but is not statistically significant in
the malignant tumour group due to a larger
variability between patients in Group 3 than
Groups 1 and 2. The variation between individual
values is clearly shown in the "scatter diagram"
(Figure 1), which emphasises the clear differences
found between first and second phases of the
menstrual cycle in relation to the IC50 values for
PG12.
The IC50 values for the malignant tumour group
(Group 3) were also considered in relation to the
existence of hypertension or obesity, and to the
occurrence of lymph node metastases. Although the
number of patients with hypertension was small,
and all were post-menopausal, there was a tendency
for the IC50 values to be increased. No apparent52 C. BENEDETTO et al.
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Figure 1 Individual values of IC50 for the effect of PG12 on ADP-induced platelet aggregation in female
control subjects and in patients with benign and malignant tumours of the breast during the first (i) and
second (ii) phase of the menstrual cycle, and after the menopause (iii).
change in the IC50 occurred in association with
obesity. In patients with lymph node metastases,
both before or after the menopause, there was no
significant change in the IC50 values compared to
corresponding patients without metastases.
Discussion
It is clear from the results presented in Table II for
female subjects that platelet sensitivity to prosta-
cyclin, as reflected by the IC50 values, is markedly
dependent upon the phase of the menstrual cycle,
and that if this is not allowed for then misleading
conclusions may ensue.
Although no special attempt was made here to
determine the variation, if any, of the IC50 with age
of women, it is evident from Table II that normal
premenopausal women (average age 28 years) have
a higher IC50 (i.e. the platelets are less sensitive to
PG12) than normal post-menopausal subjects
(average age 54 years); a decrease of IC50 with age
has been reported by Sinzinger et al. (1981).
The IC5O values obtained here for normal men
and women are in the same general range of values
reported by previous investigators, who did not
separate the female subjects into the first and
second phases of the menstrual cycle and post-
menopause. For example, our overall values for
normal females and males are 0.97+0.05 and
0.83 +0.07 ngml- 1 respectively, compared to
0.4 +0.1 ngml - 1 found by Whittle & Moncada
(1983), who did not specify the sex of the blood
donors, and 0.91 +0.07 for females and
0.92+0.09ngml-1 for males aged 41-50 years
(Sinzinger et al., 1981).
Our results with blood samples taken from
patients with benign tumours of the breast are very
similar to the results obtained with normal female
subjects (Table II, Group 1 vs. 2). In Group 2 we
have not been able to include values for post-
menopausal women as fibroadenomas in the post-
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menopause are not common (Sinkovics, 1979). The
rather smaller difference observed between the first
and second phases of the menstrual cycle in the
benign tumour group compared to normal (0.86-
1.21 compared to 0.81-1.37) may be possibly a
reflection of the higher average age in Group 2
(39 +6 years) compared to Group 1 (28+4 years).
The results found for healthy women and for
women with malignant breast tumours (Table II)
are similar to our preliminary findings (Benedetto
et al., 1984) with an important proviso that is
detailed below. In that preliminary report we
concluded from our results obtained on 9 control
and 9 malignant samples that the IC50 values for
the malignant tumour group were smaller than
those found in the control samples. However, by
chance, our early control samples were mostly from
women in the 2nd phase of the cycle (equivalent to
Group lc, Table II), and our early malignant
samples were mostly from post-menopausal women
(equivalent to Group 3e, Table II). In consequence,
our preliminary report compared women of
dissimilar hormonal status; our present results are
indeed very similar for those two groups of samples
(Group lc vs. Group 3e). However, when women of
comparable hormonal status are considered, which
is a major point emphasised here, and uncovered as
a result of this much larger study, there are no
significant differences between the normal and
tumour groups. These results show that platelets
prepared from the blood of patients with malignant
tumours of the breast are not significantly different
in their response to PG12 in relation to ADP-
induced aggregation. If platelets of cancer patients
show enhanced aggregation in vivo, as predicted by
Honn's hypothesis (Honn 1982; Honn et al., 1983)
then other contributory factors should be
investigated, such as local concentrations of PG!2
and TXA2, and sensitivity ofplatelets to TXA2.
Finally, we wish to emphasise the importance, in
studies of this kind on PG12 sensitivity, of clearly
separating the sub-groups of patients and normal
subjects with different hormonal status; unless this
is controlled then important differences between
groups under evaluation may be overlooked.
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